HMC
Harvard Management Company Portfolio holdings
AUM
$1.44B
This Quarter Return
-5.99%
1 Year Return
+33.17%
3 Year Return
+230.83%
5 Year Return
+163.57%
10 Year Return
+194.2%
AUM
$1.79B
AUM Growth
+$1.79B
(-2.9%)
Cap. Flow
+$79.8M
Cap. Flow
% of AUM
4.46%
Top 10 Holdings %
Top 10 Hldgs %
81.39%
Holding
42
New
12
Increased
7
Reduced
8
Closed
4
Top Buys
| 1 |
Intercontinental Exchange
ICE
|
$230M |
| 2 |
Adobe
ADBE
|
$155M |
| 3 |
Palo Alto Networks
PANW
|
$55.9M |
| 4 |
PureCycle Technologies
PCT
|
$32.5M |
| 5 |
Unity
U
|
$18.7M |
Top Sells
| 1 |
Royalty Pharma
RPRX
|
$173M |
| 2 |
Salesforce
CRM
|
$162M |
| 3 |
Microsoft
MSFT
|
$132M |
| 4 |
NCNA
NuCana
NCNA
|
$3.42M |
| 5 |
FSDC
FS Development Corp. Class A Common Stock
FSDC
|
$2.75M |
Sector Composition
| 1 | Healthcare | 44.96% |
| 2 | Technology | 21.24% |
| 3 | Financials | 12.87% |
| 4 | Communication Services | 7.46% |
| 5 | Consumer Discretionary | 6.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Royalty Pharma
RPRX
$15.6B
| $467M | 26.11% | 10,714,284 -3,976,496 | -27% | -$173M |
|
|
2
Intercontinental Exchange
ICE
$101B
| $230M | 12.87% | +2,062,444 | New | +$230M |
|
|
3
Adobe
ADBE
$151B
| $155M | 8.66% | +326,100 | New | +$155M |
|
4
AbCellera Biologics
ABCL
$1.25B
| $139M | 7.79% | 4,105,095 | – | – |
|
5
Meta Platforms (Facebook)
META
$1.86T
| $121M | 6.74% | 409,695 +3,155 | +0.8% | +$929K |
|
|
6
Palo Alto Networks
PANW
$127B
| $110M | 6.13% | 340,900 +173,698 | +104% | +$55.9M |
|
7
Light & Wonder
LNW
$7.76B
| $103M | 5.76% | 2,678,571 | – | – |
|
|
8
Microsoft
MSFT
$3.77T
| $61.7M | 3.45% | 261,792 -559,270 | -68% | -$132M |
|
|
9
Salesforce
CRM
$245B
| $34.9M | 1.95% | 164,622 -762,919 | -82% | -$162M |
|
10
Invesco QQQ Trust
QQQ
$364B
| $34.4M | 1.92% | 107,944 -4,821 | -4% | -$1.54M |
|
|
11
PureCycle Technologies
PCT
$2.57B
| $32.5M | 1.82% | +1,276,267 | New | +$32.5M |
|
12
Revolution Medicines
RVMD
$7.1B
| $30.8M | 1.72% | 670,382 | – | – |
|
13
iShares Core S&P 500 ETF
IVV
$662B
| $26.1M | 1.46% | 65,516 +844 | +1% | +$336K |
|
14
Praxis Precision Medicines
PRAX
$958M
| $25.5M | 1.42% | 778,517 -14,100 | -2% | -$462K |
|
15
Pliant Therapeutics
PLRX
$101M
| $22.1M | 1.24% | 562,379 | – | – |
|
16
Relay Therapeutics
RLAY
$619M
| $18.7M | 1.05% | 541,124 | – | – |
|
|
17
Unity
U
$16.7B
| $18.7M | 1.04% | +186,396 | New | +$18.7M |
|
18
10x Genomics
TXG
$1.74B
| $16.2M | 0.9% | +89,476 | New | +$16.2M |
|
19
Sana Biotechnology
SANA
$777M
| $15.7M | 0.88% | +468,749 | New | +$15.7M |
|
|
KNTE
20
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $15.5M | 0.87% | 498,001 | – | – |
|
21
SPDR Gold Trust
GLD
$107B
| $15.5M | 0.86% | 96,662 +43 | +0% | +$6.88K |
|
22
Generation Bio
GBIO
$40.4M
| $14.6M | 0.81% | 512,349 -9,111 | -2% | -$259K |
|
23
Roblox
RBLX
$86.4B
| $12.8M | 0.72% | +197,642 | New | +$12.8M |
|
24
Nurix Therapeutics
NRIX
$714M
| $9.79M | 0.55% | 314,762 | – | – |
|
25
Vanguard FTSE Developed Markets ETF
VEA
$171B
| $8.64M | 0.48% | 175,937 +1,896 | +1% | +$93.1K |
|